Biotech ETFs Had A Rough Third Quarter

Amid intensifying scrutiny of drug pricing and other political pressures, biotechnology ETFs and active mutual funds endured some rough sledding in the third quarter. The iShares Nasdaq Biotechnology ETF (IBB), VanEck Vectors Biotech ETF (BBH) and the equal-weight SPDR S&P Biotech ETF (XBI) are...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.